Probiodrug Gesellschaft für Arzneimittelforschung mbH has achieved the third milestone finishing preclinical development of its drug P32/98 for IGT and NIDDM treatment, with respect to starting a clinical phase I trial.

Probiodrug research expanding its advisory board
DM 14 million were invested mainly by the existing shareholders / Probiodrug closes private investment